Industry Analysis

A prescription for healthy returns


China’s healthcare industry is thriving in spite of a slowing economy – opening new investment vistas for global hedge fund managers, despite some already rich stock valuations in the sector

Chris Ruffle Jim Fong
Joseph Zeng Ronald Chan
Healthcare spending in China, the world’s second largest economy, is estimated to hit a record $1 trillion in 2020 as compared to about $400 billion at present – and industry experts expect that the nearly 20% annual growth witnessed by the country’s pharmaceutical market in the last decade could continue for several years more.

The dizzying pace at which China’s healthcare industry has grown has not gone un-noticed by the global hedge fund community – which is constantly